Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Relapsed or Refractory NHL
NCT00550615Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Sep 2007
- Primary completion
- Aug 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in Non-Hodgkin lymphoma (NHL), sponsored by University of Nebraska. Started Sep 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00550615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550615.